Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Novel Microenvironment-Based Immune Changes Revealed by RNA Sequencing in Cancer...
share announcement

Novel Microenvironment-Based Immune Changes Revealed by RNA Sequencing in Cancer or Metabolic Diseases

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 4069

Special Issue Editors

Prof. Dr. Yasuhito Ishigaki

E-Mail Website
Guest Editor
Medical Research Institute, Kanazawa Medical University, Kahoku 920-0293, Japan
Interests: adipose-derived stem cells; mRNA decay; noncoding RNA; RNA bindings; transcriptome analysis
Special Issues, Collections and Topics in MDPI journals
Dr. Lili Qu

E-Mail Website
Guest Editor
Health Center, University of Connecticut, Farmington, CT, USA
Interests: bioinformatics; immune; microenvironment; RNA sequencing
Dr. Baihai Jiao

E-Mail Website
Guest Editor
Department of Medicine, University of Connecticut School of Medicine, Farmington, CT 06030-1405, USA
Interests: kidney disease; immunology; inflammation; fibrosis; molecular mechanisms

Special Issue Information

Dear Colleagues,      

Microenvironment-based immune changes always happen in all types of diseases, such as cancer or metabolic diseases. These changes include not only subtypes of the immune cells but also their cellular or molecular functions. With the development of cutting-edge technologies such as RNA sequencing, CITE-seq, or ATAC-seq, tracking immune changes following the development of diseases becomes reliable, which is beneficial for the development of efficient treatments, such as immunotherapy in cancer. We invite all scientists working in the immunology field to participate in this Special Issue. Original research articles, reviews, or shorter perspective articles on all aspects related to immune changes in the microenvironment revealed by RNA sequencing are welcome, including topics such as immune cell constituent changes or molecular and cellular functional changes.

Prof. Dr. Yasuhito Ishigaki
Dr. Lili Qu
Dr. Baihai Jiao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune changes
  • RNA sequencing
  • microenvironment
  • CITE-seq
  • ATAC-seq
  • molecular changes
  • function changes
  • metabolic diseases
  • cancer

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3832 KiB  
Article
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
by Hampus Andersson, Aastha Sobti, David Gomez Jimenez, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Karin Hägerbrand, Karin Enell Smith, Malin Lindstedt and Peter Ellmark
Cells 2023, 12(19), 2365; https://doi.org/10.3390/cells12192365 - 27 Sep 2023
Cited by 1 | Viewed by 1344
Abstract
CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a potent agonistic CD40 monoclonal IgG1 antibody currently under clinical development. This study used [...] Read more.
CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a potent agonistic CD40 monoclonal IgG1 antibody currently under clinical development. This study used RNA sequencing of blood samples from a subset of patients from a Phase I trial with mitazalimab (NCT02829099) to assess peripheral pharmacodynamic activity. We found that mitazalimab induced transient peripheral transcriptomic alterations (at 600 µg/kg and 900 µg/kg dose administered intravenously), which mainly were attributed to immune activation. In particular, the transcriptomic alterations showed a reduction in effector cells (e.g., CD8+ T cells and natural killer cells) and B cells peripherally with the remaining cells (e.g., dendritic cells, monocytes, B cells, and natural killer cells) showing transcription profiles consistent with activation. Lastly, distinct patient subgroups based on the pattern of transcriptomic alterations could be identified. In summary, the data presented herein reinforce the anticipated mode of action of mitazalimab and support its ongoing clinical development. Full article
(This article belongs to the Special Issue Novel Microenvironment-Based Immune Changes Revealed by RNA Sequencing in Cancer or Metabolic Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 697 KiB  
Review
The Interplay between Immune and Metabolic Pathways in Kidney Disease
by Lili Qu and Baihai Jiao
Cells 2023, 12(12), 1584; https://doi.org/10.3390/cells12121584 - 08 Jun 2023
Cited by 11 | Viewed by 2317
Abstract
Kidney disease is a significant health problem worldwide, affecting an estimated 10% of the global population. Kidney disease encompasses a diverse group of disorders that vary in their underlying pathophysiology, clinical presentation, and outcomes. These disorders include acute kidney injury (AKI), chronic kidney [...] Read more.
Kidney disease is a significant health problem worldwide, affecting an estimated 10% of the global population. Kidney disease encompasses a diverse group of disorders that vary in their underlying pathophysiology, clinical presentation, and outcomes. These disorders include acute kidney injury (AKI), chronic kidney disease (CKD), glomerulonephritis, nephrotic syndrome, polycystic kidney disease, diabetic kidney disease, and many others. Despite their distinct etiologies, these disorders share a common feature of immune system dysregulation and metabolic disturbances. The immune system and metabolic pathways are intimately connected and interact to modulate the pathogenesis of kidney diseases. The dysregulation of immune responses in kidney diseases includes a complex interplay between various immune cell types, including resident and infiltrating immune cells, cytokines, chemokines, and complement factors. These immune factors can trigger and perpetuate kidney inflammation, causing renal tissue injury and progressive fibrosis. In addition, metabolic pathways play critical roles in the pathogenesis of kidney diseases, including glucose and lipid metabolism, oxidative stress, mitochondrial dysfunction, and altered nutrient sensing. Dysregulation of these metabolic pathways contributes to the progression of kidney disease by inducing renal tubular injury, apoptosis, and fibrosis. Recent studies have provided insights into the intricate interplay between immune and metabolic pathways in kidney diseases, revealing novel therapeutic targets for the prevention and treatment of kidney diseases. Potential therapeutic strategies include modulating immune responses through targeting key immune factors or inhibiting pro-inflammatory signaling pathways, improving mitochondrial function, and targeting nutrient-sensing pathways, such as mTOR, AMPK, and SIRT1. This review highlights the importance of the interplay between immune and metabolic pathways in kidney diseases and the potential therapeutic implications of targeting these pathways. Full article
(This article belongs to the Special Issue Novel Microenvironment-Based Immune Changes Revealed by RNA Sequencing in Cancer or Metabolic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop